Royalty Pharma
RPRX
326 hedge funds and large institutions have $9.32B invested in Royalty Pharma in 2023 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 139 increasing their positions, 107 reducing their positions, and 51 closing their positions.
313% more call options, than puts
Call options by funds: $21.9M | Put options by funds: $5.29M
30% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 107
3.26% more ownership
Funds ownership: 68.1% → 71.36% (+3.3%)
3% less funds holding
Funds holding: 335 → 326 (-9)
12% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 51
14% less capital invested
Capital invested by funds: $10.9B → $9.32B (-$1.56B)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| 1 |
SVCF
Silicon Valley Community Foundation
Mountain View,
California
|
+$532M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$47.6M |
| 3 |
Goldman Sachs
New York
|
+$45.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$38.4M |
| 5 |
Two Sigma Investments
New York
|
+$32.4M |
Top Sellers
RPRX Hedge Fund Activity: Q2 2023 in Review
326 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2023, worth a combined $9.32B — down 14% from $10.9B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of RPRX and 45 opened new positions — a net loss of 6 holders — while 107 trimmed existing stakes and 139 added.
The largest buyer was Silicon Valley Community Foundation, adding an estimated $532M. The largest seller was Fidelity Investments, cutting an estimated $207M.
- 326 institutional investors held Royalty Pharma (RPRX) as of Q2 2023, down from 335 in Q1 2023.
- Funds reported $9.32B of Royalty Pharma stock for Q2 2023, down 14% quarter-over-quarter.
- 45 funds opened new Royalty Pharma positions in Q2 2023 and 51 closed out, a net change of -6 holders.
- The largest Royalty Pharma buyer in Q2 2023 was Silicon Valley Community Foundation, an estimated $532M added.
- The largest Royalty Pharma seller in Q2 2023 was Fidelity Investments, an estimated $207M sold.
Based on aggregated 13F filings for Q2 2023.